Reimbursement Committee

Co-Chair:  Alex Azar, Eli Lilly USA
Co-Chair:  Kristine Peterson, Valeritas
Staff Contact:  Laurel Todd, Managing Director for Reimbursement and Health Policy, ltodd@bio.org.    

Subject Matter/Jurisdiction:  The Board Standing Committee on Reimbursement (BSCR) is made up of BIO Health Section Governors and focuses on reimbursement policies, including those related to Medicare, Medicaid, and other government programs, and shapes BIO’s advocacy related to patient access to innovative therapies. The committee also addresses proposals for payment system redesign, and implementation of the Patient Protection and Affordable Care Act.

Members:    

Adelene Perkins, Infinity Pharmaceuticals
Allen Waxman, Eisai                                                           
Anna Protopapas, Millennium: The Takeda Oncology Company
Christi  Shaw, Novartis Oncology
Dan Junius, ImmunoGen, Inc.
Daniel Apel, Bayer HealthCare, LLC
Daniel Tassé, Ikaria, Inc.
David Meeker, Genzyme Corporation
David Pyott,  Allergan, Inc.
Francois Nader, NPS Pharmaceuticals
Geno Germano, Pfizer, Inc.
H. Thomas Watkins, Chair Emeritus
Henri Termeer, AVEO Oncology
Hervé Hoppenot, Incyte Corporation
Jay Siegel, Johnson and Johnson
Jean Jacques Bienaimé, BioMarin Pharmaceutical, Inc.
Julie Louise Gerberding, Merck Vaccines, Merck & Co., Inc.
Kristine Peterson,  Valeritas, Inc.
Mark Timney, Purdue Pharma
Maxine Gowen, revena, Inc.
Paul Eisenberg, Amgen Inc.
Paul Hudson, Astrazeneca US
Perry Karsen, Celgene Corporation
R. John Glasspool, Baxter Healthcare Corporation
Ray Sacchetti, Bristol-Myers Squibb
Richard Pops, Alkermes, Inc.
Rick Winningham, Theravance Inc.
Roch Doliveux, UCB
Ron Cohen, Acorda Therapeutics, Inc
Steven Holtzman, Biogen Idec, Inc. 
Stuart Arbuckle, Vertex Pharmaceuticals Incorporated

Hide Date: 
Hide Date
Hide Add This: 
Hide Add This